Skip to main content

Table 2 Preclinical studies based on the use of CRISPR-Cas9 technology to provide more effective and universal CAR-T cell

From: A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Condition

CAR

Target locus (knocked out)

Study model

Ref

ALL

CD19

Pax5

Ebf1

C57Bl/6 mice

[106]

ALL

CD19

LDLR

NSG mice

[107]

Ewing sarcoma

Ganglioside G(D2)

EZH2

VH-64, RM-82, and WE-68 cell lines

NSG mice

[108]

Glioma

EGFRvIII

DGK

U87 MG line

NSG mice

[9]

Liver cancer

Ovarian cancer

Mesothelin

TGF-βRII

HepG2 , and OVCAR3 cell line

NPG mice

[29]

ALL

Prostate cancer

PSCA

CD19

TRAC

B2M

PD1

NSG mice

[109]

Glioma

CD133

PD1

U251 cell line

NPG mice

[110]

Glioma

EGFRvIII

TRAC

B2M

PD1

U87 and U251 cell line

NSG mice

[111]

Glioma

EGFRvIII

PD1

U251 cell line

[24]

BCL

CD19

LAG-3

NSG mice

[112]

BCL

CD22

TRAC

PD-1

NALM6 cell line

[113]

BCL

BCMA

CD19

TRAC

Cell line

[7]

ALL

CD7

TRAC

MOLT-3, MOLT-4, HSB-2, and CCRF-CEM cell line

NSG mice

[114]

ALL

CD19

GM-CSF

Cell line

NSG mice

[115]

ALL

CD19

GM-CSF

NALM6 and MOLM13 cell line

NSG mice

[116]

BCL

CD19

TRAC

NSG mice

[117]

ALL

CD19

TRAC

NSG mice

[118]

  1. Note: ALL acute lymphoblastic leukemia, BCL B cell lymphoma, EGFR vIII epidermal growth factor receptor variant III, PSCA prostate stem cell antigen, BCMA B cell maturation antigen, PAX5 paired box 5, EBF1 EBF transcription factor 1, LDLR low-density lipoprotein receptor, EZH2 enhancer of zeste homolog 2, DGK diacylglycerol kinase, TGF-βRII transforming growth factor beta receptor II, TRAC T cell receptor alpha constant, B2M beta-2-microglobulin, PDCD1 or PD1 programmed cell death protein 1, LAG-3 lymphocyte activation gene 3, GM-CSF granulocyte-macrophage colony-stimulating factor